血清Cyfra21-1和SELDI技术联合检测肺鳞癌的临床意义  

Clinical Significance of Cyfra21-1 Analysis Combined with SELDI-TOF-MS Technology in Lung Squamous Carcinoma

作　　者：刘枋[1,2] 林志强[3] 陈慧菁[2] 林艳[2] 林丽婷[3] 陈强[4] 叶韵斌[2] 

机构地区：[1]福建医科大学,福州350108 [2]福建省肿瘤医院肿瘤免疫学研究室 [3]福建中医学院附属人民医院检验科 [4]福建医科大学附属协和医院

出　　处：《肿瘤防治研究》2011年第5期539-541,561,共4页Cancer Research on Prevention and Treatment

基　　金：福建省自然科学基金资助项目(X0750024)

摘　　要：目的探讨血清Cyfra21-1和SELDI技术联合应用在肺鳞癌患者中的诊断意义。方法应用电化学发光技术对59例病理确诊肺鳞癌患者和60例健康对照者血清进行Cyfra21-1检测,同时应用SELDI-TOF-MS和CM10芯片检测该血清,分析两种手段的联合诊断价值。结果电化学发光法单项检测Cyfra21-1的敏感度为77.966%、特异性为96.667%。应用SELDI技术以及肺鳞癌诊断模型进行分析,敏感度为83.051%、特异性为65.385%。而联合检测的敏感度为94.915%、特异性为95.000%。结论与单用电化学发光法检测Cyfra21-1相比,联合SELDI技术检测更能提高肺鳞癌诊断的敏感度。联合检测的特异性也比单独使用SELDI技术有明显提高。Objective To study the diagnostic values of co-detections of traditional serum tumor marker（Cyfra21-1） and serum proteomic patterns by surface-enhanced laser desorption and ionization time-flight mass spectrometry（SELDI-TOF-MS） technology in patients with lung squamous carcinoma.Methods Serum samples of 59 lung squamous carcinoma patients and 60 healthy controls were detected by electrochemiluminescence to analyze the levels of Cyfra21-1,meantime SELDI-TOF-MS and CM10-chips were employed to detect the differential expressions of proteins in serum.Combined with clinical pathological materials,the diagnostic values of two methods combination were evaluated.Results The sensitivity and specificity of Cyfra21-1 detection were 77.966% and 96.667%,while SELDI-TOF-MS technology were 83.051% and 65.385%.Combined detections of two methods were 94.915% and 95.000% respectively.Conclution The sensitivity of co-detection was higher than that of single detection.The specificity of co-detection was higher than that of SELDI-TOF-MS technology.

关 键 词：肺鳞癌 SELDI CYFRA21-1 

分 类 号：R734.2[医药卫生—肿瘤]